Sexual function and serum prolactin levels in community-treated schizophrenic patients receiving aripiprazole vs standard of care

Results from the STAR study (NCT00237913)

Linda Hanssens, MS, MSPH, Gilbert L'Italien, PhD, Jean-Yves Loze, MD, MS, Ronald N Marcus, MD, Miranda Pans, MS

1 Bristol-Myers Squibb Company, Parc de l'Alliance, Avenue de Finlande, 8, B-1420 Braine-l'Alleud, Belgium

2 Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA

3 Otsuka Pharmaceutical France SAS, "Les Colonnades" -4, rue Henri Sainte Claire Deville, 92500 Rueil-Malmaison, France

§Corresponding author

Email addresses:

LH: linda.hanssens@bms.com

GLI: gilbert.litalien@bms.com

JYL: JYLoze@otsuka.fr

RNM: Ronald.Marcus@bms.com

MP: Miranda.pans@bms.com
Abstract

Background: To evaluate quality of life in relation to sexual function for treatment of schizophrenia in a community based study comparing the use of aripiprazole and standard of care (SOC) (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]).

Method: This was a multi-centre, randomised, 26-week open-label study comparing aripiprazole (starting dose 15mg/day, then 10–30 mg/day) with SOC (olanzapine, quetiapine, or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. Secondary variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the Arizona Sexual Experience scale (ASEX).

Results: A total of 555 patients were randomised to receive aripiprazole (n=284) or SOC (n=271). Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p=0.007). Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4mg/dL in the aripiprazole group and 42.3mg/dL in the SOC group, p=NS) at Week 26, mean decreases in serum prolactin were 34.2mg/dL in the aripiprazole group, compared with 13.3mg/dL in the SOC group (p<0.001).

Conclusions: The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.
Introduction

All antipsychotic medications have the potential to cause hyperprolactinaemia, as the inhibition of dopamine release effectively removes the negative feedback loop for prolactin secretion from the anterior pituitary gland [1]. Elevated serum prolactin levels have been shown to have profound effects on reproductive health and sexual function, including hypogonadism, decreased libido in both sexes, amenorrhoea and infertility in women and low sperm count and reduced muscle mass in men [2]. In addition, there is evidence to suggest a link between hyperprolactinaemia and reduced bone mineral density – a study of women with hyperprolactinaemia showed a 15–30% reduction in bone mineral density compared with healthy women [3]. There is also a suspected link between elevated plasma prolactin levels and breast cancer, although the causal relationship in this link remains to be established [1].

Sexual dysfunction associated with antipsychotic treatment is a debilitating side effect which may have a negative impact on the patient’s quality of life and adherence to treatment [4]. Clinical studies have demonstrated that with the exception of risperidone, atypical antipsychotics have significantly less impact on serum prolactin compared with conventional antipsychotics [5–9], and are also less likely to cause sexual dysfunction [10–12]. Whilst short-term clinical studies with aripiprazole have shown comparable serum prolactin levels to placebo [13], the effects of aripiprazole on serum prolactin and sexual function over a longer period of time have yet to be investigated.

The Schizophrenia Trial of Aripiprazole (STAR) study is a naturalistic effectiveness study conducted with the aim of providing critical information on the relationships between the condition, the medication, and the patients in their everyday care setting. Following an initial review of atypical antipsychotics in 2002, the UK National Institute of Health and Clinical Excellence (NICE) found a lack of ‘real-world’ data such as patient-reported outcomes, patient preferences, and treatment regimens based on the clinician’s judgment [14]. For subsequent reviews, NICE have acknowledged that whilst randomised clinical trials are of restricted applicability to the general patient population due to their limited duration and number of variables measured, naturalistic studies such as STAR allow evaluations of treatment effectiveness using less selective patient criteria and a wider spectrum of effectiveness.
variables (such as safety, tolerability, symptom relief or worsening, patient preference for medication, quality of life, and cost-effectiveness) [15,16].

The primary objective of the STAR study was to evaluate the effectiveness of a 26-week treatment of aripiprazole versus standard of care (SOC) in patients treated for schizophrenia in a community health or hospital-based outpatient setting. Outcomes research measures included quality of life and sexual function as secondary outcomes, and the safety evaluation included monitoring of serum prolactin levels. This paper will discuss specifically the findings with respect to sexual function in light of the serum prolactin analysis.
Patients and methods

Patients

Patients at 98 centres in 12 countries throughout Europe were enrolled in the study between July 2004 and June 2005. The study protocol complied with the Declaration of Helsinki and Good Clinical Practices (GCP) guidelines and was approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) at the individual study centres. Prior to study enrolment, informed written consent was obtained from all patients.

Eligible for inclusion in the study were male and female patients aged 18 to 65 years with a diagnosis of schizophrenia (DSM-IV-TR criteria) treated within a community mental health or hospital-based outpatient centre, for whom a change of antipsychotic medication was indicated due to lack of tolerability and/or symptom control as judged by the clinician.

Key exclusion criteria included acute psychotic symptoms requiring hospitalisation, risk of committing suicide, a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic brain syndrome. Patients were also excluded if they were considered treatment resistant, had had a significant psychoactive substance use disorder within 3 months prior to screening, or had any history of neuroleptic malignant syndrome, epilepsy, seizures, abnormal electroencephalogram, severe head injury, or stroke.

Study design

The design and methodology of the STAR study have been presented in detail elsewhere; hence only a summary will be provided here [17].

The STAR study was designed as a multi-centre, randomised, naturalistic, open-label study to compare aripiprazole treatment with SOC treatment. Eligible patients were randomised to receive treatment with aripiprazole or SOC for a period of 26 weeks. Patients randomised to the SOC group received one of three selected atypical antipsychotics: olanzapine, quetiapine, or risperidone, based on the investigator's/clinician's judgment as to the optimal treatment for
the individual patient and taking into account the patients’ previous response to antipsychotic medication.

A cross-titration period of up to 14 days was permitted following the randomisation, with complete discontinuation of any pre-study antipsychotic medication by Day 15. During the 26-week open-label treatment phase, study visits occurred at Weeks 2, 4, 8, 12, 18, and 26 to assess the effectiveness of study treatment.

Patients randomised to the aripiprazole group received a starting dose of 15mg/day followed by a daily dose of 10–30mg/day, as judged by the investigator, administered orally once daily independent of meals. Patients randomised to the SOC group received either olanzapine, starting at 10mg once daily followed by a daily dose of 5–20mg/day; quetiapine, starting with 50mg/day on Day 1, 100mg/day on Day 2, 200mg/day on Day 3, and 300mg/day on Day 4, then followed by an individually titrated dose of 800mg/day maximum; risperidone, starting with 2mg/day on Day 1, 4mg/day on Day 2, then a daily dose of 2–16mg/day; or dosages according to the approved local labelling for each of the three medications.

Benzodiazepines and anticholinergics were allowed during the study if deemed necessary by the investigator. Other psychotropic medications such as antidepressants and mood stabilisers were allowed if the patient was already receiving these medications when entering the study. No additional antipsychotics were allowed during the study.

Evaluations

Effectiveness assessments

Full details of the Investigator Assessment Questionnaire (IAQ) and Clinical Global Impression (CGI) Improvement (CGI-I) and Severity (CGI-S) assessments have been published elsewhere [17]. Briefly, the clinical effectiveness of the study treatments was assessed through the IAQ. The primary effectiveness variable in the trial was the mean total score of the 10-item IAQ at Week 26, last observation carried forward (LOCF).
Secondary effectiveness variables included the CGI-I and CGI-S scales. IAQ, CGI-I and CGI-S scores were obtained at Weeks 2, 4, 8, 12, 18, and at the end of Week 26.

Outcomes research assessments

The STAR study outcomes research evaluation comprised the following tools: the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), the Client Socio-demographic and Service Receipt Inventory – European version (CSSRI-EU), EuroQoL-5D (EQ-5D), Impact of Weight on Quality of Life (IWQoL-Lite), and the Arizona Sexual Experience Scale (ASEX). This paper will report and discuss the findings of the ASEX analysis; the other analyses will be reported separately.

Arizona Sexual Experience Scale (ASEX)

The ASEX is a 5-item scale to assess sexual dysfunction amongst psychiatric patients [18]. The ASEX rates sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Male and female patients are assessed separately. Possible Total Score range from 5 to 30, with the higher score indicating more patient sexual dysfunction. The scale can be either self-administered or clinician-administered and is applicable to patients regardless of the availability of a sexual partner. The ASEX was administered at baseline and at Weeks 8, 18, with a final assessment at the end of Week 26 or at the time of premature discontinuation.

Safety assessments

The safety variables of interest for this paper are the change from baseline in serum prolactin levels throughout the study, and the proportion of patients with potentially clinically significant elevations in prolactin levels. In addition to serum prolactin, the safety analysis comprised the incidence of adverse events (AEs), including treatment-emergent AEs, AEs leading to discontinuation, treatment-emergent serious AEs, and treatment-emergent EPS-related AEs.
All AEs and their relationship to study medication were recorded throughout the study. Additional safety endpoints included the proportion of subjects with potentially clinically relevant vital signs/laboratory findings as defined by the Food and Drug Administration Division of Neuropharmacological Drug Products [19], including fasting glucose, fasting total cholesterol, fasting high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and fasting triglycerides, as well as mean changes from baseline in body weight and the proportion of subjects with significant weight gain or loss (increase or decrease from baseline of ≥7%, respectively).

**Statistical procedures**

**Sample size and power**

It was estimated that 556 patients would have to be randomised to obtain 500 evaluable patients (250 on aripiprazole and 250 on SOC), assuming that 90% of the randomised patients would be evaluable in the primary endpoint. This sample size would yield 95% statistical power with a true difference in the primary endpoint of 2. This assumed a standard deviation of 6.2 and a 2-sided t-test at the 0.05 level of significance. This sample size would also allow for meaningful analysis of secondary endpoints for which it is difficult to obtain reliable estimates of variance, and for exploratory analysis to estimate the effect size of aripiprazole relative to the individual SOC items.

**Data sets**

The safety sample comprised all randomised patients who took at least one dose of study medication. The effectiveness sample included all patients in the safety sample who had at least one post-baseline effectiveness evaluation (IAQ or CGI). The outcome research sample, which included assessments of quality of life and medication preference, was comprised of all patients in the safety sample who had at least one post-baseline outcome research evaluation (including ASEX). LOCF was the primary analysis used for the effectiveness research sample.
(IAQ, CGI-I, CGI-S), whereas observed cases (OC) was the primary analysis used for the outcomes research sample (ASEX).

**Analyses**

The results from the ASEX evaluation were subject to analysis of covariance (ANCOVA) with respect to the mean change in ASEX Total Score from baseline at Week 26. The ANCOVA model included treatment group (aripiprazole, SOC) and gender as the main effect, with the baseline score as a covariate. Each additional OC week and each LOCF week was analysed similarly. For the analysis of LOCF data, country was also included as a main effect within the model. In addition, the baseline ASEX Total Score was analysed with an ANOVA model including for treatment group and gender (and country for the LOCF data set).

The proportion of patients with potentially clinically relevant laboratory test values during the 26-week period was summarised by treatment group. A proportion of patients with potentially clinically relevant selected laboratory test values (i.e. fasting metabolic lab tests) during the 26-week period were analysed using a Cochran-Mantel-Haenszel test controlling for the presence or absence of baseline abnormality.

The change from baseline in serum prolactin, glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were analysed using ANCOVA model which included treatment group and fasting status as main effects and baseline value as the covariate. Fasting status was a factor of four levels (baseline fasting/on-treatment value fasting, baseline fasting/on-treatment value nonfasting, baseline nonfasting/on-treatment value fasting, and baseline nonfasting/on-treatment value nonfasting). Baseline serum prolactin, glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were analysed with an ANOVA model which included treatment group and baseline fasting status (yes, no). For the analysis of serum prolactin, fasting status was not included within the models. All laboratory values except serum prolactin were analysed with respect to the subset of patients who had a fasting baseline assessment and fasting on-treatment assessments.
Results

The demographics, primary efficacy results and safety findings of the STAR study have been presented in detail elsewhere [17]. This paper will present the results of the patient-reported secondary endpoint ASEX and the safety endpoint serum prolactin levels.

Patient disposition and demographics

A total of 593 patients were enrolled into the study and 555 patients were randomised to receive study treatment with aripiprazole (n=284) or SOC (n=271) for 26 weeks. Of patients randomised to receive SOC, 75 patients received olanzapine, 110 patients received quetiapine, and 81 patients received risperidone. Five patients in the SOC group were randomised, but never received study medication. Table 1 shows the baseline demographic characteristics of the randomised patient population. Patient disposition data are summarised in Table 2.

The most common reason for a change in medication in accordance with the study inclusion criteria were poorly controlled positive (aripiprazole 32%, SOC 22%) and negative symptoms (aripiprazole 25%, SOC 32%), followed by weight gain (aripiprazole 12%, SOC 12%). The mean daily dose of study medication at the end of the treatment period was 18.7mg aripiprazole, 12.5mg olanzapine, 386.8mg quetiapine, and 4.6mg risperidone.

Clinical effectiveness and outcomes

Primary efficacy outcomes

The results of the primary effectiveness analysis (IAQ, GCI-I and CGI-S scores) in the STAR study have been described in detail elsewhere [17].

Patient-reported secondary outcomes: sexual function (ASEX)
Both treatment groups experienced improvements in sexual function from baseline as assessed by ASEX; the improvement was significantly greater in the aripiprazole group compared with the SOC group (Figure 1). The difference in favour of aripiprazole was statistically significant from Week 8 (first assessment point) onwards. At 26 weeks, the ASEX Total Score had dropped by 1.88 points from 19.27 at baseline, compared with a drop of 0.92 from 19.7 at baseline in the SOC group (p=0.032).

Safety

Adverse events

The results of the safety analysis have been reported in detail elsewhere [17]. In summary, the incidence of treatment-emergent AEs was similar in both treatment groups (77% in the aripiprazole group versus 71% in the SOC group). The most common AEs (≥10%) were insomnia, anxiety, headache, and nausea in the aripiprazole group, and anxiety and somnolence in the SOC group.

Serum prolactin levels

Baseline mean serum prolactin levels were similar in the two treatment groups (43.4mg/dL in the aripiprazole group and 42.3mg/dL in the SOC group, p=NS). At week 26, mean decreases in serum prolactin were 34.2mg/dL in the aripiprazole group, compared with 13.3mg/dL in the SOC group (p<0.001; OC) (Figure 2). The maximum on-treatment effect on serum prolactin levels in the safety sample was a mean reduction of 28.8mg/dL in the aripiprazole, versus a mean increase of 0.3 mg/dL in the SOC group (p<0.001).

Potentially clinically relevant elevations in prolactin levels during the 26-week period were seen in a significantly higher proportion of patients in the SOC group (136 patients [54.4%]) compared with the aripiprazole group (45 patients [16.8%]).
Discussion

The STAR study was designed to allow comparison of aripiprazole with SOC treatment in a setting close to daily clinical practice, and also to assess the patient and caregiver perspective on the treatment received. The primary outcome measure in the STAR study was the IAQ total score, which takes into account both the efficacy and tolerability of an antipsychotic medication and thus is a measure of effectiveness rather than merely efficacy [20]. The results of STAR demonstrated clearly that at all time points, treatment with aripiprazole was associated with significantly better effectiveness compared with SOC treatment, in the form of one of three atypical agents chosen by the clinician as optimal treatment for the individual patient.

The results of the ASEX evaluation and the serum prolactin measurement in the STAR study showed that patients treated with aripiprazole experienced significantly less sexual dysfunction as measured by the ASEX scale, and were more likely to have normal serum prolactin levels at the end of the treatment period compared with patients receiving SOC. These findings are consistent with the existing body of evidence for atypical antipsychotics, as discussed below.

Whilst sexual dysfunction has traditionally run the risk of being underestimated in clinical trials due to the lack of self-reporting and unwillingness to discuss the issue, there is increasing awareness amongst clinicians and allied mental health care professionals that sexual dysfunction is a common and distressing side effect of antipsychotic medication [21]. A survey carried out by the UK patient advocacy group Rethink (formerly the National Schizophrenia Fellowship) showed that 66% of patients who had experienced sexual dysfunction felt that this side effect was ‘bad’ or ‘very bad’ [22]. Men appear to suffer more than women [21]. Overall, around half of all patients treated with antipsychotics experience sexual dysfunction; the associated distress and frustration may have a profound effect on the quality of life of the patient, and is likely to lead to non-compliance with the antipsychotic treatment regimen [23–25].
Prolactin plays a key role in the regulation of sexual behaviour and activity [26], and elevated serum prolactin levels associated with antipsychotic medication are known to cause erectile dysfunction, orgasmic difficulties, amenorrhoea and gynaecomastia [10,27]. The implications of sexual dysfunction for treatment compliance and prevention of relapse, together with the potential link between primary and secondary prolactinaemia and breast cancer and/or decreased bone mineral density [28] makes serum prolactin an important endpoint in the assessment of antipsychotic therapy. A growing evidence base indicates that with the exception of risperidone, the atypical antipsychotics are less associated with hyperprolactinaemia than conventional antipsychotics. Some agents, including quetiapine, olanzapine and clozapine, were shown at an early stage to cause no significant or sustained increase in serum prolactin in adult patients [5–9]. More recently, a systematic review of short-term clinical trials with aripiprazole showed that the effect of aripiprazole on serum prolactin levels was comparable to that of placebo, and significantly lower than that of risperidone [13]. That a reduced incidence of elevated serum prolactin levels translates into less potential for sexual side effects was demonstrated in the Intercontinental Schizophrenia Outpatient Health Outcomes IC-SOHO study, which showed that patients receiving olanzapine or quetiapine experienced significantly less sexual dysfunction compared with patients receiving risperidone or haloperidol [12]. Switching patients from conventional antipsychotics or risperidone to an antipsychotic with less potential for prolactin elevation is therefore likely to be an effective measure for improving treatment compliance and reducing the risk of symptomatic relapse in patients experiencing sexual dysfunction during antipsychotic therapy.

One major limitation to the interpretation of the findings is that the STAR study employed an open-label design and both patients and physicians would have been aware as to whether they were receiving study medication or not. This may have introduced bias in subjective measures such as the ASEX, and caution should thus be exercised when interpreting these results.

Conclusions
In conclusion, the results of this study show that treatment with aripiprazole has the potential to improve not only the clinical effectiveness, but also to reduce the potential for sexual dysfunction, which is increasingly held to be one of the most distressing side effects associated with antipsychotic treatment, as well as the risk of severe side effects associated with hyperprolactinaemia such as loss of bone mineral density and osteoporosis. By removing the distress associated with sexual dysfunction, compliance can potentially be improved and the risk of relapse might be reduced, making aripiprazole an attractive option for providing effective and acceptable care for patients with schizophrenia and their carers.
Competing interests


Authors' contributions

LH and GLI participated in the design of the trial, particularly choosing the research instruments used in the study for patient research and economic outcomes. JYL provided monitoring for the conduct of the study and medical review at the country level. RNM provided validation of the study design and protocol as the clinical research lead. MP participated in the design of the study and performed the statistical analysis. All authors were involved in preparing the manuscript and, read and approved the final manuscript.

Acknowledgements

This study was supported by Bristol-Myers Squibb Company (Princeton, NJ) and Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). The authors would like to thank the STAR study investigators for conducting the trial. Editorial support for the preparation of this manuscript was provided by Healthcare Education Services; funding was provided by Bristol-Myers Squibb Company.
References


### Tables

**Table 1. Baseline demographic characteristics of the randomised patient population [17].**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Aripiprazole (N=284)</th>
<th>All SOC (N=271)</th>
<th>Total (N=555)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, y</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>38.1</td>
<td>38.3</td>
<td>38.5</td>
</tr>
<tr>
<td>Median</td>
<td>36.5</td>
<td>37.0</td>
<td>37.0</td>
</tr>
<tr>
<td>SE</td>
<td>10.8</td>
<td>11.1</td>
<td>10.9</td>
</tr>
<tr>
<td><strong>Gender, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>169 (59.5)</td>
<td>163 (60.1)</td>
<td>332 (59.8)</td>
</tr>
<tr>
<td>Female</td>
<td>115 (40.5)</td>
<td>108 (39.9)</td>
<td>223 (40.2)</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>274 (96.5)</td>
<td>262 (96.7)</td>
<td>536 (96.6)</td>
</tr>
<tr>
<td>Black</td>
<td>3 (1.1)</td>
<td>1 (0.4)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Asian</td>
<td>3 (1.1)</td>
<td>6 (2.2)</td>
<td>9 (1.6)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (1.4)</td>
<td>2 (0.8)</td>
<td>6 (1.1)</td>
</tr>
<tr>
<td><strong>Weight, kg</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schizophrenia type, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>Disorganised</td>
<td>24</td>
<td>32</td>
<td>56</td>
</tr>
<tr>
<td>Catatonic</td>
<td>3</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Paranoid</td>
<td>189</td>
<td>172</td>
<td>361</td>
</tr>
<tr>
<td>Residual</td>
<td>31</td>
<td>36</td>
<td>67</td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>37</td>
<td>27</td>
<td>64</td>
</tr>
</tbody>
</table>

**Age at time of first hospitalisation, y**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>28.3</td>
<td>28.7</td>
</tr>
<tr>
<td>Median</td>
<td>27.0</td>
<td>27.0</td>
</tr>
<tr>
<td>SE</td>
<td>8.5</td>
<td>8.7</td>
</tr>
</tbody>
</table>
Table 2. Summary of patient disposition [17].

<table>
<thead>
<tr>
<th>Patient Status</th>
<th>Number of patients (%)</th>
<th>Aripiprazole</th>
<th>All SOC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluated for study inclusion</td>
<td></td>
<td></td>
<td></td>
<td>593</td>
</tr>
<tr>
<td>Randomised</td>
<td></td>
<td>284</td>
<td>271</td>
<td>555</td>
</tr>
<tr>
<td>Randomised, but did not receive study medication (due to non-compliance, adverse event, withdrawn consent or protocol violation)</td>
<td></td>
<td>2</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Discontinuation from treatment phase</td>
<td></td>
<td>120 (42.3)</td>
<td>105 (38.7)</td>
<td>225 (40.5)</td>
</tr>
<tr>
<td>Lack of efficacy</td>
<td></td>
<td>33 (11.6)</td>
<td>20 (7.4)</td>
<td>53 (9.5)</td>
</tr>
<tr>
<td>Adverse event</td>
<td></td>
<td>57 (20.1)</td>
<td>43 (15.9)</td>
<td>100 (18.0)</td>
</tr>
<tr>
<td>Withdrew consent</td>
<td></td>
<td>8 (2.8)</td>
<td>18 (6.6)</td>
<td>26 (4.7)</td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td>1 (0.4)</td>
<td>2 (0.7)</td>
<td>3 (0.5)</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td></td>
<td>6 (2.1)</td>
<td>6 (2.2)</td>
<td>12 (2.2)</td>
</tr>
<tr>
<td>Poor or non-compliance</td>
<td></td>
<td>10 (3.5)</td>
<td>10 (3.7)</td>
<td>20 (3.6)</td>
</tr>
<tr>
<td>Pregnancy</td>
<td></td>
<td>2 (0.7)</td>
<td>2 (0.7)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Non longer meets study criteria</td>
<td></td>
<td>2 (0.7)</td>
<td>3 (1.1)</td>
<td>5 (0.9)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>1 (0.4)</td>
<td>1 (0.4)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>Completed treatment phase</td>
<td></td>
<td>164 (57.7)</td>
<td>166 (61.3)</td>
<td>330 (59.5)</td>
</tr>
</tbody>
</table>
Figure Legends

Figure 1: Mean change from baseline in total ASEX score (OC).

Figure 2: Mean change from baseline in serum prolactin concentration (OC).
Mean change from baseline in ASEX total score

Week 8: Aripiprazole (Baseline 215, SOC Baseline 208) with *P=0.007
Week 18: Aripiprazole (Baseline 188) and SOC (Baseline 182) with +P=0.002
Week 26: Aripiprazole (Baseline 161) and SOC (Baseline 157) with **P=0.032

Figure 1
Figure 2

Week 4 | Week 8 | Week 12 | Week 18 | Week 26
-------|--------|---------|---------|---------
Aripiprazole Baseline = 43.4mg/dL
SOC Baseline = 42.3mg/dL

* P<0.001

Baseline 224: 217, 203, 185, 164
Baseline 209: 208, 192, 180, 158